CARDIO DIAGNOSTICS HOLDINGS (CDIO)

Company Profile

Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2021-11-23. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD, is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its second product, PrecisionCHD, is an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Its Epi+Gen CHD and PrecisionCHD tests are categorized as laboratory-developed tests (LDTs), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers and payors.

Company Info

CARDIO DIAGNOSTICS HOLDINGS

311 W. Superior Street, Suite 444

Chicago ILLINOIS

P: 18552269991

Employees: 7

Website: http://www.cardiodiagnosticsinc.com